Pegylated Kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis

Cancer Research

Volumn 69, Issue 21, 2009, Pages 8395-8402

  Li, Wei ^a   Wang, Bu Er ^a   Moran, Paul ^a   Lipari, Terry ^a   Ganesan, Rajkumar ^a   Corpuz, Racquel ^a   Ludlam, Mary J C ^a   Gogineni, Alvin ^a   Koeppen, Hartmut ^a   Bunting, Stuart ^a   Gao, Wei Qiang ^a   Kirchhofer, Daniel ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; HEPSIN; PEGYLATED KUNITZ DOMAIN 1 INHIBITOR; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SERINE ENDOPEPTIDASES; TUMOR CELLS, CULTURED;

EID: 70350523855     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1995     Document Type: Article

References (42)

1. Netzel-Arnett S, Hooper JD, Szabo R, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 2003;22: 237-258 (Pubitemid 36561060)
2. Wu Q, Parry G. Hepsin and prostate cancer. Front Biosci 2007;12:5052-5059
3. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-826 (Pubitemid 32801464)
4. Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61: 4683-4688 (Pubitemid 32691876)
5. Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61:5692-5696 (Pubitemid 32769078)
6. Stamey TA, Warrington JA, Caldwell MC, et al. Molecular genetic profiling of Gleason grade 4/5prostate cancers compared to benign prostatic hyperplasia. J Urol 2001;166:2171-2177
7. Stephan C, Yousef GM, Scorilas A, et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 2004; 171:187-191 (Pubitemid 37549120)
8. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61: 5974-5978
9. Xuan JA, Schneider D, Toy P, et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res 2006;66:3611-3619
10. Morrissey C, True LD, Roudier MP, et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 2008;25:377-388
11. Tanimoto H, Yan Y, Clarke J, et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 1997;57: 2884-2887 (Pubitemid 27315033)
12. Zacharski LR, Ornstein DL, Memoli VA, Rousseau SM, Kisiel W. Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost 1998;79:876-877
13. Betsunoh H, Mukai S, Akiyama Y, et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 2007;98:491-498 (Pubitemid 46562738)
14. Matsuo T, Nakamura K, Takamoto N, et al. Expression of the serine protease hepsin and clinical outcome of human endometrial cancer. Anticancer Res 2008;28: 159-164 (Pubitemid 351362896)
15. Torres-Rosado A, O'Shea KS, Tsuji A, Chou SH, Kurachi K. Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc Natl Acad Sci U S A 1993;90:7181-7185 (Pubitemid 23222413)
16. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002;62:6812-6816 (Pubitemid 35424064)
17. Miao J, Mu D, Ergel B, et al. Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. Int J Cancer 2008;123:2041-2047
18. Nakamura K, Takamoto N, Abarzua F, et al. Hepsin inhibits the cell growth of endometrial cancer. Int J Mol Med 2008;22:389-397
19. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004;6: 185-195 (Pubitemid 39485690)
20. Vasioukhin V. Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 2004;3: 1394-1397 (Pubitemid 40310675)
21. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 2005;579: 1945-1950.
22. Herter S, Piper DE, Aaron W, et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 2005;390: 125-136 (Pubitemid 41192238)
23. Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, Quaranta V. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem 2008;283:30576-30584
24. Kelly KA, Setlur SR, Ross R, et al. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res 2008;68:2286-2291
25. Beliveau F, Desilets A, Leduc R. Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides. FEBS J 2009;276:2213-2226
26. Shimomura T, Denda K, Kitamura A, et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997;272:6370-6376 (Pubitemid 27118113)
27. Kirchhofer D, PeekM, Li W, et al. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem 2003;278:36341-36349 (Pubitemid 37139961)
28. Fan B, Wu TD, Li W, Kirchhofer D. Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J Biol Chem 2005;280:34513-34520 (Pubitemid 41504581)
29. Shia S, Stamos J, Kirchhofer D, et al. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol 2005;346:1335-1349 (Pubitemid 40248833)
30. Kojima K, Tsuzuki S, Fushiki T, Inouye K. Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase. J Biol Chem 2008;283:2478-2487
31. Peek M, Moran P, Mendoza N, Wickramasinghe D, Kirchhofer D. Unusual proteolytic activation of prohepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J Biol Chem 2002;277:47804-47809 (Pubitemid 36159306)
32. Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchhofer D. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 2006;281:30439-30446 (Pubitemid 44596152)
33. Morrison JF. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 1969;185:269-286
34. Olivero AG, Eigenbrot C, Goldsmith R, et al. A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem 2005;280: 9160-9169 (Pubitemid 41818227)
35. Devy L, Rabbani SA, Stochl M, et al. PEGylated DX- 1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia 2007;9:927-937 (Pubitemid 350086438)
36. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004;91:31-67. (Pubitemid 39140956)
37. Cozzi PJ, Wang J, Delprado W, et al. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 2006;37:1442-1451 (Pubitemid 44584322)
38. Usher PA, Thomsen OF, Iversen P, et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 2005;113:870-880 (Pubitemid 40096866)
39. Dennis MS, Lazarus RA. Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection. J Biol Chem 1994; 269:22137-22144 (Pubitemid 24282139)
40. Wu Q, Yu D, Post J, Halks-Miller M, Sadler JE, Morser J. Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease. J Clin Invest 1998;101:321-326 (Pubitemid 28067328)
41. Yu IS, Chen HJ, Lee YS, et al. Mice deficient in hepsin, a serine protease, exhibit normal embryogenesis and unchanged hepatocyte regeneration ability. Thromb Haemost 2000;84:865-870
42. Guipponi M, Tan J, Cannon PZ, et al. Mice deficient for the type II transmembrane serine protease, TMPRSS1/hepsin, exhibit profound hearing loss. Am J Pathol 2007;171:608-616 (Pubitemid 47344693)